Enliven Therapeutics, Inc./$ELVN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Enliven Therapeutics, Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Ticker
$ELVN
Sector
Primary listing
Employees
63
Headquarters
Website
ELVN Metrics
BasicAdvanced
$1.2B
-
-$2.00
1.03
-
Price and volume
Market cap
$1.2B
Beta
1.03
52-week high
$24.38
52-week low
$13.30
Average daily volume
532K
Financial strength
Current ratio
32.583
Quick ratio
32.247
Long term debt to equity
0.042
Total debt to equity
0.042
Profitability
EBITDA (TTM)
-113.926
Management effectiveness
Return on assets (TTM)
-17.19%
Return on equity (TTM)
-25.26%
Valuation
Price to book
2.5
Price to tangible book (TTM)
2.5
Price to free cash flow (TTM)
-14.588
Free cash flow yield (TTM)
-6.86%
Free cash flow per share (TTM)
-1.413
Growth
Earnings per share change (TTM)
4.23%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Enliven Therapeutics, Inc. stock?
Enliven Therapeutics, Inc. (ELVN) has a market cap of $1.2B as of October 27, 2025.
What is the P/E ratio for Enliven Therapeutics, Inc. stock?
The price to earnings (P/E) ratio for Enliven Therapeutics, Inc. (ELVN) stock is 0 as of October 27, 2025.
Does Enliven Therapeutics, Inc. stock pay dividends?
No, Enliven Therapeutics, Inc. (ELVN) stock does not pay dividends to its shareholders as of October 27, 2025.
When is the next Enliven Therapeutics, Inc. dividend payment date?
Enliven Therapeutics, Inc. (ELVN) stock does not pay dividends to its shareholders.
What is the beta indicator for Enliven Therapeutics, Inc.?
Enliven Therapeutics, Inc. (ELVN) has a beta rating of 1.03. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.